Navirel (Vinorelbine)

Navirel (vinorelbine) is employed in oncology for malignancies that rely on rapid cell division.

• Non‑small cell lung cancer: improves disease control and overall survival in advanced stages.
• Breast cancer (adjuvant setting): used as part of combination regimens to reduce recurrence risk.
• Metastatic breast cancer: provides palliation and tumor burden reduction when combined with other agents.

• Vinorelbine binds to tubulin, inhibiting microtubule polymerisation and disrupting mitotic spindle formation. This arrests cells in the M phase of the cell cycle, leading to apoptosis of rapidly dividing tumor cells. The drug’s action is independent of DNA synthesis and primarily affects proliferating cancer cells.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional, may require anti‑emetic support.
• Neutropenia: reduced white blood cell count, increasing infection risk.
• Alopecia: hair loss that is usually reversible.
• Fatigue: generalized tiredness during treatment cycles.
• Constipation: bowel motility changes requiring dietary management.

Serious or Rare Side Effects

• Severe neutropenia with febrile infection: requires immediate medical attention.
• Pulmonary toxicity: dyspnoea or interstitial pneumonitis.
• Peripheral neuropathy: tingling or numbness of extremities.
• Anaphylactic reaction: rare but potentially life‑threatening hypersensitivity.
• Cardiac arrhythmia: irregular heart rhythms observed in susceptible patients.

Before initiating Navirel, clinicians should assess patient suitability and monitor for potential complications.

• Blood count monitoring: perform complete blood counts before each cycle to detect neutropenia.
• Liver function assessment: evaluate hepatic enzymes as vinorelbine is metabolised hepatically.
• Neuropathy evaluation: avoid in patients with pre‑existing peripheral neuropathy.
• Cardiac risk review: use cautiously in patients with known cardiac disease or arrhythmias.
• Concomitant myelosuppressants: avoid or adjust doses when combined with other bone‑marrow suppressing agents.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with several drug classes, influencing efficacy or toxicity.

Major Interactions (Avoid)

• Concurrent vinca alkaloids: additive myelosuppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase vinorelbine exposure.
• Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels.
• Anticoagulants (warfarin, DOACs): enhanced bleeding risk.
• Diuretics: potential for electrolyte disturbances when combined with vinorelbine‑induced nausea.